The Anatomy of Olfactory Transport — From Nasal Epithelium to Olfactory Bulb
The upper portion of the nasal cavity is lined with a specialised sensory surface called the olfactory epithelium, a thin tissue bed in which the dendrites of olfactory receptor neurons are exposed directly to the air. These neurons do not behave like ordinary sensory cells. Their axons project without interruption through the cribriform plate of the skull and terminate in the olfactory bulb, which sits at the anterior base of the brain. The result is a continuous cellular pathway from outside the skull to inside it, entirely bypassing the tight-junction endothelium of the blood-brain barrier.
Peptides applied to this epithelium can be taken up by olfactory receptor neurons and transported axonally into the olfactory bulb. Radiolabelled tracer studies in animals have tracked this movement, and the pharmacokinetics are well-characterised at the qualitative level: transport is real, relatively rapid, and does not require systemic circulation as an intermediary. From the olfactory bulb, the transported molecule has access to interconnected anterior brain structures including the prefrontal cortex and hippocampus. These are precisely the regions where cognitive peptides such as Semax and Selank are expected to act.
This anatomical fact underpins the 'bypasses the blood-brain barrier' claim. It is technically accurate — molecules transported through olfactory neurons never enter the bloodstream at all during their passage to the brain. Where the claim becomes problematic is in the implication that brain delivery is therefore complete or efficient.
The Trigeminal Pathway — the Second Nose-to-Brain Route
Alongside the olfactory pathway, the trigeminal nerve provides a second route from nasal mucosa to brain. The trigeminal nerve's ophthalmic and maxillary branches innervate the nasal mucosa extensively; their fibres project centrally to the brainstem rather than to the olfactory bulb, providing access to a different but overlapping set of brain regions.
The trigeminal pathway is somewhat more capacious than the olfactory route in terms of mucosal surface area, but it delivers primarily to brainstem and periventricular structures rather than to the cortex directly. Its contribution to the cognitive effects of peptides like Semax is harder to quantify than the olfactory contribution, and most research designs do not attempt to dissect the two pathways independently.
Together, however, the olfactory and trigeminal routes make intranasal administration genuinely distinct from other peripheral routes in terms of CNS access. No other non-invasive delivery method provides a structural connection to brain tissue that bypasses the blood-brain barrier entirely. This is the legitimate scientific basis for the intranasal approach.
What 'Bypassing the Blood-Brain Barrier' Actually Means (and Doesn't Mean)
When researchers write that intranasal peptides bypass the blood-brain barrier, they are making a claim about route, not about efficiency. The transported fraction (the portion of the applied dose that actually reaches brain tissue via the olfactory or trigeminal pathways) is a minority of the total dose applied to the nasal mucosa.
Much of any intranasally applied compound undergoes the same fate as any other nasal spray: it is cleared by mucociliary transport to the pharynx, swallowed, and exposed to gastrointestinal proteases. A fraction is absorbed directly into the nasal mucosal vasculature and enters systemic circulation. Only the fraction that contacts the olfactory epithelium specifically, and survives long enough to be taken up by olfactory neurons, reaches the brain by the barrier-bypassing route.
For small, relatively stable peptides (and Semax and Selank are both more stable than they might appear from their amino-acid sequences), this olfactory fraction is measurable and pharmacologically significant. For larger or rapidly degraded peptides, it is not. The intranasal route is not a guarantee of CNS delivery; it is an enabling condition for a transport mechanism that operates in parallel with, and often in smaller magnitude than, systemic absorption.
Why Bioavailability Is Sub-Parenteral and Highly Variable
Even in ideal conditions, intranasal CNS bioavailability for peptides falls well short of what can be achieved by direct injection. Intravenous or subcutaneous administration delivers the entire dose to systemic circulation; from there the blood-brain barrier is the only obstacle, and many peptides cross it at least partially. Intranasal administration delivers only a fraction of the dose to the pathway that bypasses the barrier, and the remaining fraction faces the same blood-brain barrier crossing challenge as any systemic compound.
Published estimates for CNS bioavailability via the olfactory route vary substantially between compounds and between studies. The consistent finding is that intranasal delivers meaningfully more peptide to the brain than the same dose given orally, since oral administration typically produces near-zero CNS exposure for peptides due to gastrointestinal proteolysis, but meaningfully less than parenteral injection.
Factors That Determine How Much Peptide Reaches the Brain
Several variables modulate the efficiency of nose-to-brain transport from one subject or session to the next. Nasal mucosal condition is primary: congestion, rhinitis, or mucosal inflammation reduce the exposed olfactory epithelium area and slow or stop transport. A subject with a head cold during an intranasal Semax protocol is likely to show substantially reduced CNS delivery.
Vehicle formulation matters considerably. The carrier solution's pH affects peptide stability and mucosal absorption. Preservatives can denature some peptides. Volume per dose affects how much material reaches the olfactory region versus how much flows anteriorly into the main nasal passage. Head positioning at the time of administration determines whether the applied dose runs toward the olfactory region or drains away from it.
Species differences complicate the translation of animal data to humans. Rodents have a far larger olfactory epithelium relative to total nasal mucosa area than humans do. Studies in rats and mice therefore tend to show higher nose-to-brain transport efficiency than would be expected in human subjects at comparable doses, and published animal pharmacokinetics should not be applied directly to human research design.
Why Vehicle Formulation and Head Position Matter in Intranasal Research Protocols
Research protocols using intranasal peptides typically specify both the vehicle formulation and the head position during and after administration. These specifications are not arbitrary precautions. They are mechanistically grounded parameters that directly affect how much peptide contacts the olfactory epithelium.
The olfactory epithelium occupies the uppermost portion of the nasal cavity. To maximise contact, the head needs to be positioned so that the applied liquid moves upward and posteriorly toward that region rather than draining anteriorly out of the naris or posteriorly into the nasopharynx. The Kaiteki or 'sniff' position (head tilted down and forward) is the conventional research standard for maximising olfactory contact.
Vehicle pH matters because the olfactory epithelium maintains tight pH homeostasis, and peptides applied in solutions outside the physiological range of 6.5 to 7.5 trigger protective mucosal responses that can accelerate peptide clearance. Buffered saline at physiological pH is the standard vehicle for most intranasal peptide research precisely because it minimises this effect.
Comparing Intranasal with IV and Subcutaneous Routes for Peptide Delivery
The practical choice between intranasal, intravenous, and subcutaneous routes in peptide research involves a tradeoff between CNS delivery efficiency, invasiveness, and practical experimental considerations.
Intravenous delivery is most efficient for systemic exposure and avoids the variability of mucosal uptake entirely. For compounds that cross the blood-brain barrier adequately, it provides the most controllable pharmacokinetic profile. For compounds like Semax that are rapidly degraded in plasma, however, IV delivery produces very brief CNS exposure — the compound is cleaved within minutes of injection.
Subcutaneous delivery offers a longer absorption phase and is preferred for some peptides where sustained low-level systemic exposure is more useful than a brief spike. It is also more practical for repeated dosing in research settings than IV. The blood-brain barrier crossing requirement still applies.
Intranasal delivery's distinctive advantage over both routes is not bioavailability but mechanism: direct neural transport that deposits the compound in the brain without the blood-brain barrier as a filter. For the nose-to-brain intranasal delivery research overview, this anatomical specificity is precisely what makes the route scientifically interesting for peptide CNS research, not the raw efficiency numbers, but the ability to investigate CNS effects in the absence of the confounds introduced by systemic distribution. The variability remains a real limitation that should be acknowledged explicitly in any intranasal protocol design.
